Nurix Therapeutics, Inc. Stock Price, News & Analysis

Nurix Therapeutics (NASDAQ: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CEO, Dr. Arthur T. Sands, and CFO, Hans van Houte, will engage in a fireside chat on June 4, 2025, at 3:45 p.m. ET in New York. The presentation will be available through a live webcast on Nurix's website, with the recording remaining accessible for 30 days following the event.

Nurix Therapeutics (NRIX) has granted inducement awards to 13 new employees on May 13, 2025, as part of their 2024 Equity Inducement Plan. The awards include stock options to purchase 87,950 shares of common stock at $9.73 per share and restricted stock unit awards (RSUs) for 60,050 shares.

The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will also vest over 4 years, with 25% vesting after one year and the remainder vesting quarterly. Both awards are subject to continued employment.

Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, announced its participation in the upcoming RBC Capital Markets Global Healthcare Conference. The company's Chief Financial Officer Hans van Houte and Chief Business Officer Jason Kantor, Ph.D., will engage in a fireside chat on Wednesday, May 21, 2025, at 2:05 p.m. ET in New York, NY. The presentation will be available through a live webcast on Nurix's website in the Investors section, with the recording remaining accessible for 30 days following the event.

Nurix Therapeutics (NRIX) announced upcoming presentations of clinical data for their drug bexobrutideg (NX-5948) at two major scientific conferences in June 2025. The data comes from ongoing Phase 1a/b clinical trials studying the drug's effects on patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia.

The presentations will take place at the European Hematology Association Congress (EHA 2025) in Milan and the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano. The data will be featured in two posters at EHA 2025 and in both an oral presentation and poster at 18-ICML, focusing on bexobrutideg's clinical responses and safety profile as a novel Bruton's tyrosine kinase (BTK) degrader.

Nurix Therapeutics unveiled groundbreaking data at the AACR 2025 Annual Meeting showcasing their innovative DEL-AI platform, which combines DNA-encoded libraries with machine learning to accelerate drug discovery.

The company's DEL Foundation Model, developed in collaboration with Loka and supported by Amazon Web Services, demonstrates remarkable capabilities in:

• Accurately predicting novel drug binders for therapeutic targets
• Working with as little as 50% amino acid sequence similarity
• Identifying potential treatments for previously "undruggable" targets
• Inferring binders from chemical space outside training data

This AI-powered platform represents a significant advancement in drug discovery, potentially streamlining the identification of small molecule drugs, protein degraders, and molecular glues. The technology leverages Nurix's extensive database of over five billion unique DEL compounds screened against hundreds of disease targets and E3 ligase proteins.

The presentation, titled "DEL-AI: Proteome-wide in silico screening of multi-billion compound libraries using machine learning foundation models," validates the platform's ability to perform virtual DEL experiments and accurately predict experimental results.

Nurix Therapeutics (NRIX) presented positive preclinical data at AACR 2025 for multiple orally available, brain-penetrant protein degraders targeting three oncology targets. Bexobrutideg, their lead BTK degrader, demonstrated exceptional efficiency by degrading approximately 10,000 BTK copies per hour at clinically relevant concentrations.

The company showcased NRX-0305, a BRAF degrader effective across all three BRAF mutation classes while sparing healthy cells. It showed superior anti-tumor efficacy in resistant tumors compared to competitor CFT1946 and demonstrated effectiveness in combination with MEKi.

Additionally, Nurix presented data on NRX-4972, an orally bioavailable Aurora A kinase degrader developed in collaboration with Alex's Lemonade Stand Foundation. This degrader showed significant efficacy in neuroblastoma models, inducing DNA damage, apoptosis, and G2/M arrest more effectively than traditional inhibitors.

Nurix Therapeutics (NRIX) announced FDA clearance of their IND application for GS-6791/NX-0479, a novel IRAK4 degrader developed for inflammatory conditions. The Phase 1 trial is set to begin in Q2 2025, focusing on single and multiple ascending dose studies in healthy volunteers.

The development triggers a $5 million milestone payment from collaboration partner Gilead Sciences, bringing total payments under their 2019 agreement to $135 million. Nurix remains eligible for additional $420 million in milestones plus potential royalties.

GS-6791/NX-0479 has shown promising preclinical results, demonstrating rapid IRAK4 degradation across multiple human cell types and robust efficacy in arthritis models. The drug targets inflammatory conditions including rheumatoid arthritis and atopic dermatitis. Nurix retains the option to co-develop and co-detail in the US, with a 50/50 split of profits and losses.

Nurix Therapeutics (NRIX) has granted inducement awards to 16 new employees on April 8, 2025, as part of their 2024 Equity Inducement Plan. The awards include:

- Stock options to purchase 79,950 shares with a 10-year term at $9.26 per share exercise price
- Restricted stock units (RSUs) representing 54,750 shares

The stock options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. RSUs also vest over 4 years, with 25% vesting on April 30, 2026, and the remainder vesting quarterly. Both awards require continued employment with Nurix for vesting.

Nurix Therapeutics (NRIX) reported Q1 2025 financial results and corporate updates. The company's lead BTK degrader NX-5948 received the nonproprietary name 'bexobrutideg' and FDA Orphan Drug Designation for Waldenström macroglobulinemia. Revenue increased to $18.5M from $16.6M year-over-year, including $7M in Sanofi collaboration milestones.

The company achieved significant milestones, including a $15M license extension fee from Sanofi and strengthened its leadership with Roy D. Baynes joining the board and John Northcott as chief commercial officer. R&D expenses rose to $69.7M from $50.0M, while G&A expenses slightly decreased to $11.7M.

The company reported a net loss of $56.4M ($0.67 per share) compared to $41.5M ($0.76 per share) in the previous year. Nurix maintains a strong financial position with $549.7M in cash and marketable securities, excluding recent milestone payments.